Solid Biosciences (NASDAQ:SLDB) Stock Rating Upgraded by Truist Financial

Solid Biosciences (NASDAQ:SLDB) was upgraded by stock analysts at Truist Financial to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.

Other equities analysts have also recently issued reports about the stock. Chardan Capital reaffirmed a “buy” rating and issued a $15.00 target price on shares of Solid Biosciences in a report on Friday, March 20th. Wedbush reiterated an “outperform” rating and set a $14.00 price target on shares of Solid Biosciences in a research note on Wednesday, March 11th. Needham & Company LLC reissued a “buy” rating and set a $19.00 price objective on shares of Solid Biosciences in a research report on Friday, March 20th. Citigroup restated a “market outperform” rating on shares of Solid Biosciences in a research note on Wednesday, December 17th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Solid Biosciences in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $16.09.

Solid Biosciences Stock Up 6.9%

NASDAQ:SLDB opened at $7.73 on Wednesday. The company has a market capitalization of $602.24 million, a PE ratio of -3.83 and a beta of 2.65. Solid Biosciences has a 52-week low of $2.41 and a 52-week high of $8.72. The stock’s 50 day moving average price is $6.57 and its 200 day moving average price is $5.84.

Solid Biosciences (NASDAQ:SLDB) last issued its quarterly earnings data on Thursday, March 19th. The company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.01. As a group, sell-side analysts anticipate that Solid Biosciences will post -2.84 EPS for the current fiscal year.

Insider Activity

In related news, insider Gabriel Brooks sold 12,616 shares of Solid Biosciences stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $6.44, for a total value of $81,247.04. Following the transaction, the insider directly owned 84,092 shares in the company, valued at $541,552.48. This trade represents a 13.05% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Alexander Cumbo sold 16,644 shares of Solid Biosciences stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $5.82, for a total transaction of $96,868.08. Following the completion of the transaction, the chief executive officer owned 235,405 shares in the company, valued at approximately $1,370,057.10. This trade represents a 6.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 597,672 shares of company stock valued at $3,816,546. 1.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Legal & General Group Plc lifted its position in Solid Biosciences by 208.6% in the second quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock valued at $29,000 after purchasing an additional 4,063 shares during the period. Ameritas Investment Partners Inc. boosted its holdings in Solid Biosciences by 205.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock valued at $33,000 after purchasing an additional 4,534 shares in the last quarter. Creative Planning acquired a new position in Solid Biosciences during the 2nd quarter worth approximately $57,000. Russell Investments Group Ltd. raised its stake in shares of Solid Biosciences by 142.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,211 shares of the company’s stock worth $63,000 after buying an additional 5,991 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its position in Solid Biosciences by 233.8% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 15,113 shares of the company’s stock worth $74,000 after acquiring an additional 10,585 shares in the last quarter. 81.46% of the stock is owned by hedge funds and other institutional investors.

More Solid Biosciences News

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Truist upgraded SLDB to “Strong‑Buy”, adding a near‑term positive catalyst that supports momentum and investor confidence. Zacks Article
• Positive Sentiment: JPMorgan raised its price target from $11 to $12 and maintained an “Overweight” rating — a ~55% upside vs. the current share level — which can attract institutional interest and buying. Benzinga Article
• Positive Sentiment: HC Wainwright raised multiple near‑term EPS estimates (Q1–Q4 2026) and materially improved its FY2026 outlook (from ~($2.12) to ($1.43)), while keeping a “Buy” rating and a $20 price target — signaling better expected near‑term performance and strong long‑term upside (FY2029–2030 turn to profitability). HC Wainwright Coverage
• Neutral Sentiment: Analyst optimism is concentrated in price targets and model revisions rather than new clinical readouts or revenue — the moves reflect expectations, not confirmed commercial progress; watch for upcoming company data or milestones to sustain gains. MarketBeat Summary
• Negative Sentiment: Consensus remains that Solid is not yet profitable (street FY current consensus still negative), so the stock is vulnerable to execution risk, trial setbacks, or any misses vs. these raised expectations. MarketBeat Financials

About Solid Biosciences

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.